BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres †-Reference-Cited by-同舟云学术

BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres †

Published:2021-01-09 Issue:3 Volume:192 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Ghesquières Hervé¹²^ORCID,Dalban Cécile³,Nicolas‐Virelizier Emmanuelle¹,Jardin Fabrice⁴,Le Bras Fabien⁵,Le Gouill Steven⁶,Casasnovas Olivier⁷,Vizoso Séraphine³,Hernandez Caroline³,Metzger Séverine³,Pérol David³,Cartron Guillaume⁸

Affiliation:

1. Department of Hematology Centre Léon Bérard, Université Claude Bernard Lyon 1 LyonFrance

2. Department of Hematology Hôpital Lyon Sud, Université Claude Bernard Lyon 1 Pierre BéniteFrance

3. Department of Clinical Research and Innovation Centre Léon Bérard LyonFrance

4. Centre Henri Becquerel, Inserm U1245 Université de Rouen, IRIB RouenFrance

5. Department of Hematology CHU Henri Mondor CreteilFrance

6. Service d’Hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes‐Angers NeXT Université de Nantes NantesFrance

7. Department of Hematology CHU Dijon Bourgogne and INSERM 1231 DijonFrance

8. Department of Hematology, CHU Montpellier, UMR 5535 Université de Montpellier Montpellier France

Funder

Mundipharma International

Publisher